Tirzepatide is a dual agonist at both the GIP and GLP-1 receptors. Acting on two incretin pathways rather than one, it is evaluated within medical weight management and cardiometabolic programs where appetite regulation and glucose control are both priorities.
Format & administration
A once-weekly subcutaneous injection with a stepwise titration schedule. Dose increases are spaced to allow tolerance to build, and your doctor determines when and whether to escalate.
Testing posture
Your doctor determines the final testing requirements for Tirzepatide after reviewing your intake. The panels below are what is commonly reviewed for this therapy — they are educational guidance, not a fixed requirement.
How it works
How Tirzepatide works
01GLP-1 receptor activity reduces appetite and slows gastric emptying, while GIP receptor activity contributes to insulin sensitivity and how fat tissue handles nutrients.
02Together the two pathways address both intake and metabolic handling of what is eaten.
Tirzepatide: proposed mechanism, physiology, and reported clinical effects. Educational illustration — not a treatment guarantee.
Show illustration: Tirzepatide
Tirzepatide: proposed mechanism, physiology, and reported clinical effects. Educational illustration — not a treatment guarantee.
What has been studied
Potential applications and evidence
These areas are commonly discussed within wellness-focused protocols. They are educational statements, not medical claims or guarantees of outcome.
Doctor-directed weight management
Appetite regulation and satiety
Insulin sensitivity and glycemic markers
Cardiometabolic risk factors reviewed with labs
Doctor-guided
A personalized approach
Your doctor determines the final testing requirements for Tirzepatide after reviewing your intake. The panels below are what is commonly reviewed for this therapy — they are educational guidance, not a fixed requirement.
Bloodwork status: Baseline Labs Generally Required
Commonly reviewed at baseline
A1c and fasting glucose
Comprehensive metabolic panel (CMP)
Lipid panel
Thyroid panel (TSH)
Pregnancy status where applicable
Follow-up & monitoring
Each dose escalation is reviewed for tolerance, with weight trend and A1c reassessed at roughly 12-week intervals.
Medication review
Your doctor reviews all prescriptions, supplements, and over-the-counter medications during intake before anything is prescribed.
Format & dosing
A once-weekly subcutaneous injection with a stepwise titration schedule. Dose increases are spaced to allow tolerance to build, and your doctor determines when and whether to escalate.
Safety
What patients should know
Compounded tirzepatide is not an FDA-approved product and is prepared for an individual patient pursuant to a valid prescription. Gastrointestinal effects — nausea, constipation, reflux, early fullness — are the most frequently reported and are managed with titration pace. Not appropriate with a personal or family history of medullary thyroid carcinoma or MEN2, a history of pancreatitis, active gastroparesis, or during pregnancy or nursing.
Who may not be a candidate
Pregnancy or nursing
Active malignancy without oncology clearance
Known hypersensitivity to the preparation
Personal or family history of medullary thyroid carcinoma or MEN2
History of pancreatitis
Active gastroparesis
Regulatory status: Compounded. Evidence level: Established. Eligibility, dosing, laboratory requirements, and follow-up care are determined exclusively by a licensed doctor after review of your history.